表紙
市場調查報告書

CHC (消費者保健) 產業上CBD (大麻二酚):20個問題

CBD 2020 The 20 Most Important Questions about CBD in the Future of CHC

出版商 Nicholas Hall & Company 商品編碼 916326
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
CHC (消費者保健) 產業上CBD (大麻二酚):20個問題 CBD 2020 The 20 Most Important Questions about CBD in the Future of CHC
出版日期: 2020年03月16日內容資訊: 英文 124 Pages
簡介

大麻二酚(一種大麻提取物)在許多全球市場中都在爆炸性暢銷,從藥品和補品到食品,飲料和化妝品。但是,急速成長的同時無法滿足監管要求,考慮加入的企業面臨著棘手的問題。

本報告提供CHC (消費者保健) 產業上CBD (大麻二酚)的市場調查,彙整大麻·CBD定義和概要,CBD健康上的優點,CHC產業上重要性,風險和副作用,目前法律規章和修改預測,市場規模的轉變·預測,主要企業的簡介,CBD認證的條件,今後展望等資料。

第1章 CHC產業上CBD (大麻二酚)的重要性

  • 簡介
  • 許多效果
  • CBD:顛覆性類別
  • CBD:很多成分
  • CBD和MNC
  • 以色列的前例

第2章 大麻(Cannabis, marijuana)·醫療大麻的差異?

  • 市場定義

第3章 CBD對健康有哪些好處

  • CBD的健康上的功效
  • CBD的抗痙攣效果:其他症狀的適應可能性
  • 要點

第4章 CBD的風險·副作用

  • 我們所知道的
  • 我們不知道的
  • 矛盾·相互作用
  • 克服CBD的安全性的相關疑慮

第5章 目前法律制度

  • 北美
  • 歐洲
  • 亞洲
  • 南美
  • 非洲

第6章 法律規章的修改預測

第7章 CBD市場規模

  • 美國
  • 加拿大
  • 中國
  • 英國
  • 瑞士
  • 德國
  • 澳洲
  • 義大利
  • 法國
  • 日本

第8章 CBD市場預測

第9章 CBD的使用者

  • 用戶的擴大
  • 美國消費者
  • 歐洲消費者
  • 總論

第10章 主要企業

  • Canopy Growth
  • Aurora
  • GW Pharmaceu&cals
  • Aphria
  • Curaleaf
  • Tilray
  • Creso Pharma
  • Mile High Labs
  • 其他的主要M&A

第11章 CBD認證要件

第12章 處方藥改列成藥或者補充品:最好的策略是什麼?

第13章 CBD給藥形態的多樣化

  • 各種形態可利用的CBD
  • CBD油·酊劑:仍然最受歡迎
  • 透過各種形態的產品銷售

第14章 CBD如何影響其他消費者

第15章 CBD的價格設定

第16章 電子商務如何影響CBD的增長?

第17章 CBD供應鏈的主要課題

第18章 如何建立控制下的市場信賴

第19章 對CHC經營者來說的主要課題

第20章 今後展望

目錄

CBD the cannabis extract has exploded in popularity across many world markets, from pharmaceuticals and supplements to food & beverages and cosmetics. As fast as it is growing, CBD remains confounded by regulatory issues, while consumer healthcare players looking to get involved face burning questions that must be answered.

For the first time, Nicholas Hall's Reports investigates and answers the 20 most important questions about CBD facing the CHC industry. In an all-new format, this feature report dives into the issues surrounding when and how players should respond to the enormous commercial potential of CBD, across diverse healthcare and retail categories.

In doing so, the report will answer critical questions such as:

  • What is the current regulatory status of CBD in leading world markets, and how will it change?
  • Should marketers wait for OTC switch of CBD or enter the expanding supplements segment?
  • What are the main challenges?
  • What will prices and margins look like?
  • How strong are the health claims, and is CBD here to stay?

Table of Contents

1. Why does CBD maFer to CHC?

  • Introduc&on
  • A plethora of effects
  • CBD is disrup&ng categories
  • CBD: the omni-ingredient
  • CBD and MNCs
  • The Israeli precedent

2. Cannabis, marijuana, medical cannabis,

  • hemp, CBD ... what's the difference?
  • Defining the market

3. What are the health benefits of CBD

  • and how strong is the evidence?
  • CBD's health claims
  • Can CBD's an&-seizure effect be extrapolated to
  • other condi&ons?
  • The boFom line

4. What are the risks & side-effects of CBD?

  • What we know
  • What we don't know
  • Contraindica&ons / interac&ons
  • Overcoming concerns about CBD's safety

5. What is the current regulatory status of CBD?

  • North America
  • Europe
  • Asia
  • La&n America
  • Africa

6. What are the expected changes in

  • CBD regula&on?
  • The CBD molecule is legal and should remain legal
  • CBD products are in regulatory stasis....
  • Regulatory expecta&ons 2020-21
    • USA
    • Europe
  • The boFom line

7. How big is the CBD market?

  • Global CBD sales booming
  • USA
  • Canada
  • China
  • UK
  • Switzerland
  • Germany
  • Australia
  • Italy
  • France
  • Japan

8. How big can the CBD market get?

  • Looking to the future of CBD markets around the world
  • Forecasts

9. Who is using CBD?

  • CBD's user base is diverse and expanding
  • US consumers
  • European consumers
  • Conclusion

10. Who are the main players in CBD?

  • Canopy Growth
  • Aurora
  • GW Pharmaceu&cals
  • Aphria
  • Curaleaf
  • Tilray
  • Creso Pharma
  • Mile High Labs
  • Other key M&A

11. What is needed to give the regulatory

  • green light to CBD?
  • Resolving issues of CBD's classifica&on in the USA
  • EU defines CBD as a novel food
  • UK blazes a trail in na&onal CBD regula&on

12. Switch or supplements - what is the

  • best strategy?
  • Should marketers wait to switch from Rx to OTC
  • rather than play in the supplement shallows?

13. How are CBD's delivery formats diversifying?

  • Vast range of formats available
  • CBD oils and &nctures remain most popular
  • Launch ac&vity broadens range of delivery formats

14. How is CBD impac&ng other consumer

  • goods categories?
  • CBD is finding its way into a host of consumer goods
  • categories
  • Dermatologicals & beauty
  • Seda&ves & sleep aids
  • Oral health
  • Other innova&ons in edibles & supplements

15. How is CBD priced?

  • What do prices for CBD look like?

16. How is e-Commerce impac&ng CBD growth?

  • CBD sales via online channels

17. What are the main CBD supply chain issues?

  • The CBD journey

18. How do marketers develop trust in an

  • under-regulated market?
  • The importance of trust
  • What about regula&on?
  • Addressing concerns, building trust
  • Different levels of transparency

19. What are the main challenges for

  • CHC players?
  • Challenge 1: CBD's status amid regulatory uncertainty
  • Challenge 2: Differen&a&ng in a saturated market
  • Challenge 3: Overcoming supply chain issues

20. What's next?

  • Regulatory approval - the path ahead
  • More data
  • Resolving confusion around CBD as drug or supplement
  • Managing formula&on and contamina&on concerns
  • CBD around the world
  • Are trace cannabinoids the future?
  • Will consumer demand stay strong?